Figure 1
ELISA heat map of discovery set samples. We performed sequential ELISA as described in “Antibody array methods” on samples from 21 GVHD− patients (left panel) and 21 GVHD+ patients (right panel) of the discovery set that were analyzed by microarray in Figure S1. Gray indicates that the sample was not assayed for that protein. Levels of PSA-ACT, IL-17, and IL-1β were not detectable and therefore do not appear in the figure. We measured tumor-necrosis-factor-receptor-1 (TNFR1) rather than TNF-α because of its close correlation to TNF-α and documented reproducibility of measurement in previously frozen samples.1P values compare GVHD+ and GVHD− samples.

ELISA heat map of discovery set samples. We performed sequential ELISA as described in “Antibody array methods” on samples from 21 GVHD patients (left panel) and 21 GVHD+ patients (right panel) of the discovery set that were analyzed by microarray in Figure S1. Gray indicates that the sample was not assayed for that protein. Levels of PSA-ACT, IL-17, and IL-1β were not detectable and therefore do not appear in the figure. We measured tumor-necrosis-factor-receptor-1 (TNFR1) rather than TNF-α because of its close correlation to TNF-α and documented reproducibility of measurement in previously frozen samples.P values compare GVHD+ and GVHD samples.

Close Modal

or Create an Account

Close Modal
Close Modal